Drug Trial Radar · NCT02617459
Levobetaxolol Hydrochloride Eye Drops for Treatment of Primary Open-angle Glaucoma or Ocular Hypertension
Last checked: Nov 20, 2026Latest source record: May 12, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
366
Actual
Start
Jan 4, 2019
Primary completion
Jul 1, 2021
Study completion Jul 1, 2021
Sponsor
- Lead sponsor
- Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 1, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the safety and efficacy of Levobetaxolol in Chinese patients with glaucoma.
Conditions
- Primary Open-angle Glaucoma
- Ocular Hypertension
Interventions
Levobetaxolol eye dropsDrug
one drop per time; twice daily
Betaxolol eye dropsDrug
one drop per time; twice daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in intraocular pressure (IOP) from baseline at week 8 after the treatment (a.m.)Time frame: 8 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Zhongshan ophthalmic center, Sun Yat-sen University
Guangzhou, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.